Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Links:
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis …
https://bit.ly/3bMz2r7
08-11-2021